Skip to content

Not yet independently audited

This page was written from verified sources but has not yet passed the independent citation audit. Treat its claims as provisional.

Guidelines

TL;DR — Major guidelines generally address nonspecific low-back pain rather than DDD as a discrete disease. They agree on screening for serious pathology, avoiding routine imaging in uncomplicated presentations, education/activity, nonpharmacologic care and caution with opioids; they differ in recommended modalities, medicines and procedural thresholds (Qaseem 2017, PMID 28192789; Cancelliere 2023, PMID 37991650). Spine-society and interventional guidance becomes more phenotype- and procedure-specific but often relies on lower-certainty evidence (Chou 2009, PMID 19363455; Navani 2019, PMID 30717500). A guideline recommendation cannot convert incidental degeneration into a validated pain generator.

Scope problem

Guideline scope Population Relevance to DDD
Nonspecific low-back pain Broad primary-care pain First-line management
Chronic primary low-back pain Persistent pain without specific cause Rehabilitation and medicines
Radicular pain/sciatica Root-related symptoms Epidural/decompression pathway
Lumbar fusion Selected chronic axial/surgical disease High-stakes selection
Disc replacement Narrow one/two-level DDD Device-specific eligibility
Interventional pain Procedure candidates Blocks, ablation, intradiscal care
Regenerative medicine Investigational biologics Governance and evidence grading

Recommendations must be read within their population, date and health system.

Major guidance families

Body/family Region Main scope General direction
ACP 2017 United States Acute/subacute/chronic low-back pain Nonpharmacologic first; selective medicines
WHO 2023 Global Chronic primary low-back pain Person-centered package; avoid isolated low-value care
NICE NG59 England/Wales Low-back pain and sciatica Risk stratification, activity, limited imaging; psychological-therapy recommendations withdrawn July 2026
NASS North America Diagnosis/treatment and procedures Phenotype/procedure-specific
APS evidence review United States Surgery/interventions Cautious for nonspecific axial pain
ASIPP United States/international membership Interventional/regenerative procedures More permissive for selected interventions
Multidisciplinary national guidelines Various Primary care/rehabilitation Broad agreement, modality variation
CSSLS/CAS multidisciplinary consensus 2026 China Low-back pain by etiology, including discogenic pain Conservative care first; weak recommendations for selected intradiscal, fusion and disc-replacement options

September 2026 additions

A new multidisciplinary guideline addresses acute low-back pain lasting less than six weeks, with or without radiculopathy, in outpatient care. Its development used systematic review and GRADE methodology. The 2026-09-30 sweep verified the abstract and publication record only; the 2026-10-14 sweep reconciled it with AAPM's clinician page, below. It should not be treated as a chronic DDD guideline or a demonstrated replacement for the existing chronic-care documents (Skelly 2026, PMID 42687437).

The September ASIPP paper is an analytical summary of the 2025 regenerative guideline, not a new independent efficacy study or a replacement guideline. It reports Level III/fair evidence and moderate consensus-based recommendations for intradiscal PRP and BMAC; this grading should remain distinguished from product-specific, sham-controlled efficacy and disc regeneration (Manchikanti 2026, PMID 42804305).

October 2026 additions

AAPM acute guideline, recommendation level. AAPM's guideline hub no longer says "Coming Soon"; it now links a dedicated acute-low-back-pain guideline page naming Skelly, Kansagara, Oswald and Chou. Its clinician summary covers adults with atraumatic pain for less than six weeks. It advises against routine imaging unless red flags are present, and it starts with education, reassurance, staying active, superficial heat and a short course of over-the-counter NSAIDs if safe. If symptoms are unchanged after 1–2 weeks, the listed options, in no priority order, are optimised NSAIDs, a skeletal muscle relaxant, exercise-based physical therapy, psychologically informed physical therapy for people at risk of chronic pain, spinal manipulation/mobilisation and acupuncture. Carisoprodol is not recommended. Systemic steroids and epidural steroid referral are "Radiculopathy Only - Low Certainty Evidence", with "no evidence supporting these options for isolated nonradicular back pain". Opioids are not to be used routinely as initial treatment (AAPM — "Acute Low Back Pain Guideline - Clinician Resources", https://www.painmed.org/acute-low-back-pain-clinicians, accessed 2026-10-14; Skelly 2026, PMID 42687437). These are the society's own summary bullets, not grades extracted from the full guideline. The guideline remains an acute-pain document and adds nothing specific to a disc phenotype.

Chinese multidisciplinary consensus (Bone Research, 2026). The Chinese Society for the Study of the Lumbar Spine and the Chinese Association of Spine published a consensus that grades recommendations as strong or weak, for or against. It drew on 653 publications selected from 4,703 retrieved (Gao 2026, PMID 42660880). Its population explicitly includes discogenic low-back pain, alongside herniation, stenosis, facet, sacroiliac, myofascial, instability-related and inflammatory pain. This makes it one of the few guidance documents that issues recommendations against a named discogenic phenotype. Its recommendation wording was checked against the open-access full text (PMC13522480):

Intervention Consensus wording (full text) Stated evidence/grade
Lumbar interbody fusion "may be weakly recommended" for selected chronic discogenic pain, among other indications, "when symptoms and imaging are concordant" Level I, Grade B
Total disc replacement "may be considered a weak recommendation for selected patients with chronic discogenic low back pain after failed conservative care" Level I/II, Grade B
Intradiscal glucocorticoid weak recommendation for chronic discogenic pain "with active discopathy or modic changes" Level I, Grade B
Intradiscal MSC "weakly recommended investigational treatment option", preferably within approved or registered studies Level I, Grade C
Intradiscal PRP boxed statement names "ankylosing spondylitis–related chronic low-back pain"; the body text concludes "weakly recommended for selected patients with chronic discogenic low back pain" Level I, Grade B
IDET; intradiscal radiofrequency thermocoagulation only "under research, audit, or strict governance conditions"; thermocoagulation "not recommended as routine care" —

Three features matter for this condition. First, the PRP recommendation is internally inconsistent: the boxed statement and the body text name different populations, and the evidence paragraph also cites a sacroiliac-joint PRP trial. Second, the full text contains no mention of basivertebral or intraosseous nerve ablation, or of vertebrogenic pain. Its intradiscal-steroid recommendation is the only one keyed to Modic change. Third, its weak-for recommendations on fusion and disc replacement directly contradict NICE NG59. NICE says do not offer disc replacement, and do not offer fusion except within a randomised trial. This contradiction is an instance of the scope and values disagreement tabulated below, not an error in either document.

PRP evidence after the consensus. A 2026 systematic review and meta-analysis of 11 RCTs (623 patients) in chronic discogenic pain found "no significant differences ... in pain and functional improvement between PRP and control groups at any time point". It rated the certainty of evidence very low. Only one trial reported a replicable preparation method (Madrazo-Ibarra 2026, PMID 42852874; abstract only, full text publisher-blocked). Its search ran to April 2025. The Chinese consensus searched to December 2025 yet graded the same intervention Level I/Grade B, so both evidence windows overlap. Neither document supersedes the other.

Cost-effectiveness of guideline-recommended LBP care. A PLoS Medicine systematic review searched ten databases to 9 February 2026 and included 20 papers (17 trial-based economic evaluations and three models) reporting 24 studies and 55 comparisons with usual care (Mathieson 2026, PMID 42945153; publisher full text). All evidence came from nine high-income countries. The authors did not pool ICERs because of heterogeneous perspectives, time horizons and cost structures. From that narrative synthesis, several guideline-endorsed non-pharmacologic, non-surgical interventions—including yoga, acupuncture, cognitive therapies, fear/stress-reduction approaches and self-management support—were often cost-effective at a £20,000/QALY threshold, and some comparisons were cost-saving versus usual care. Massage alone was not. This is an economic synthesis for nonspecific LBP, not a DDD-specific recommendation, and it does not replace clinical-efficacy grading. Low- and middle-income cost evidence remains limited; SciELO and LILACS could not be searched in this sweep (HTTP 403 / JS-shell limits).

Official-site checks on 2026-10-28 found no replacement of NICE NG59 (still last updated 29 July 2026), VA/DoD 2022, NASS 2021 LBP, WHO 2023, or AAPM's clinician summary. KCE study 2026-13 remains listed under planned projects. NASS's "2026 Biologic Interventions for Spinal Pathologies" listing is a November course, not a new clinical practice guideline.

ACP 2017

ACP recommends nonpharmacologic care first for chronic low-back pain, including exercise, multidisciplinary rehabilitation, acupuncture, mindfulness-based stress reduction, tai chi, yoga, motor-control exercise, progressive relaxation, biofeedback, cognitive behavioral therapy and spinal manipulation, with evidence strength varying (Qaseem 2017, PMID 28192789).

If response is inadequate, NSAIDs are first-line pharmacologic therapy; tramadol or duloxetine are second-line; opioids are reserved for selected cases after discussion of known risks and realistic benefit (Qaseem 2017, PMID 28192789).

The supporting systematic review found generally small benefits and limited long-term evidence for medicines (Chou 2017, PMID 28192790).

WHO chronic primary low-back-pain guideline evidence

WHO commissioned a coordinated systematic-review series and applied a chronic primary low-back-pain frame (Cancelliere 2023, PMID 37991650).

Intervention evidence review Finding emphasis PMID
Structured exercise Benefits/harms across programs 37991647
Education/advice Structured education and advice 37991651
TENS Uncertain/variable benefit 37991646
Needling Benefits, harms and certainty 37991648
Methodological recommendations Better rehabilitation trials 37991649

The WHO approach emphasizes combinations tailored to the person rather than one isolated intervention. DDD-specific imaging is not a prerequisite for this pathway.

NICE NG59

NICE addresses low-back pain and sciatica in people aged 16 and older. Its core approach includes risk stratification, self-management and exercise, with manual therapy only "as part of a treatment package that includes exercise" (1.2.7). Routine imaging in non-specialist settings is discouraged unless serious pathology is suspected or imaging is likely to change management.

July 2026 amendment. NICE "withdrew the recommendations on psychological therapy for low back pain with or without sciatica, and combined physical and psychological programmes" (former 1.2.13 and 1.2.14). It also removed references to psychological therapy from 1.1.3, on risk stratification, and 1.2.7, on manual therapy. The stated reason is that a surveillance review found the recommendations "may be out of date, but an update was not prioritised" (NICE — "Low back pain and sciatica in over 16s: update information", https://www.nice.org.uk/guidance/ng59/chapter/Update-information, accessed 2026-10-14). This is a withdrawal, not a recommendation against psychological care: NG59 is now silent on it. It should not be read as new evidence that psychological approaches are ineffective. The invasive-treatment recommendations are unchanged: do not offer spinal injections for low-back pain (1.3.1), fusion only within an RCT (1.3.9), and do not offer disc replacement (1.3.10).

NICE recommendations differ from ACP on some modalities and medicines because evidence thresholds, update dates, cost-effectiveness and NHS delivery context differ. The guideline should be checked for current amendments before use.

Imaging agreement

Across primary-care guidelines, imaging is generally reserved for:

  • suspected serious pathology;
  • severe/progressive neurological deficit;
  • persistent radicular disease when invasive treatment is considered;
  • specialist planning when results will change management.

High asymptomatic prevalence supports this policy (Brinjikji 2015, PMID 25430861). Guideline implementation studies show passive publication alone changes practice poorly (Riis 2016, PMID 27769263).

Exercise and rehabilitation agreement

Most guidelines recommend staying active and structured exercise for persistent low-back pain. They rarely identify one universally superior exercise type.

Point Consensus Residual disagreement
Activity Avoid prolonged bed rest Exact flare pacing
Exercise Offer structured program Type, dose and supervision
Psychological care Use when relevant/combined Which approach and intensity; NICE NG59 withdrew its recommendations in July 2026 without replacement
Multidisciplinary rehab For complex persistent disability Access and cost thresholds
Work Facilitate participation Program ownership and timing

Exercise evidence is broad low-back-pain evidence, not disc-regeneration evidence (Hayden 2021, PMID 34580864; Fleckenstein 2022, PMID 35914641).

Medicines

Class Common guideline direction Disagreement/uncertainty
NSAIDs Selective short-term use Risk stratification and duration
Acetaminophen Not effective alone for routine low-back pain Some legacy guidance differs
Muscle relaxants Short acute use in some guidelines Sedation and class heterogeneity
Duloxetine Option in some chronic-pain guidance Access, adverse effects
Gabapentinoids Discouraged for nonspecific axial pain Neuropathic phenotype boundary
Opioids Avoid routine/long-term use Exceptional-case wording
Benzodiazepines Generally discouraged Acute spasm legacy use

An overview of Cochrane reviews confirms small and uncertain average pharmacologic effects (Cashin 2023, PMID 37014979). A review of guideline-recommended medicines found inconsistency across documents (Price 2022, PMID 35562756).

Injections

Guidelines separate radicular epidural injection from axial DDD. Epidural steroids may be considered for short-term radicular relief; evidence does not support them as a structural treatment for disc degeneration (Shamliyan 2014, PMID 24787344).

Intradiscal thermal, steroid and biologic procedures receive variable recommendations because diagnosis and trial quality differ. Interventional guidelines tend to grade selected evidence more favorably than general-medicine guidelines.

Basivertebral nerve ablation

Basivertebral ablation postdates several major low-back-pain guidelines. Randomized trials support selected chronic axial pain with Modic 1/2 changes (Fischgrund 2018, PMID 29423885; Khalil 2019, PMID 31229663).

Policy questions include:

  • duration and adequacy of conservative care;
  • allowed levels and Modic types;
  • radicular/stenosis exclusions;
  • osteoporosis and prior-surgery exclusions;
  • requirement for independent replication;
  • long-term registry surveillance.

Fusion

Surgical guidance generally rejects fusion for imaging degeneration alone. Evidence reviews found fusion can improve selected chronic pain but does not show a large universal advantage over intensive rehabilitation (Chou 2009, PMID 19363455; Phillips 2013, PMID 23334400).

Guideline disagreement often concerns how much diagnostic confidence and failed care are enough, because no level-selection test is fully validated (Willems 2013, PMID 23427903).

Disc replacement

Device and spine guidance limits lumbar arthroplasty to selected one- or two-level symptomatic DDD with suitable facets, alignment, bone quality and anatomy. Meta-analyses of randomized trials find noninferiority or modest advantages on some endpoints versus fusion (Rao 2014, PMID 24323061; Wei 2013, PMID 23645003).

Guidelines must remain device- and era-specific; one implant’s results do not establish a class lifetime effect.

Regenerative medicine

ASIPP issued guidance on responsible use of biologics and later evidence updates (Navani 2019, PMID 30717500; Manchikanti 2025, PMID 41481869).

General caveats:

Requirement Rationale
Regulatory-compliant product Identity/sterility/potency
Trial or registry Evidence generation
Transparent pricing Avoid therapeutic misconception
Long-term safety Tumor/ectopic tissue/late infection
Standard rehabilitation Control co-intervention
No “stem-cell cure” claims Evidence remains investigational

Positive cell trials justify further research, not generic commercial class approval (Gornet 2024, PMID 38925869; Pers 2024, PMID 39393844).

Red flags

Guidelines list many red flags, but systematic review found individual flags often have poor diagnostic accuracy (Downie 2013, PMID 24335669; Verhagen 2016, PMID 27376890).

Suspected condition Higher-value clues Action principle
Cauda equina Urinary retention, saddle sensory change, severe deficits Emergency pathway
Malignancy Cancer history, systemic pattern Contextual imaging/workup
Fracture Major trauma, older age, steroid/osteoporosis risk Imaging based on probability
Infection Fever, immunosuppression, injection/IV drug risk Urgent labs/imaging
Inflammatory disease Young onset, extra-articular features Rheumatologic assessment

Absence of one red flag should not be used as a rule-out test.

Why recommendations disagree

Source of disagreement Example consequence
Different populations Primary care vs procedure candidates
Evidence cutoff date New ablation/cell trials omitted
Evidence grading Same trial judged moderate vs low certainty
Values/preferences Small benefit vs treatment burden
Cost-effectiveness Health-system-specific access
Specialty composition Procedure thresholds differ
Conflicts of interest Device/biologic interpretation

Disagreement is content to document, not noise to average.

Implementation

Guideline adherence requires decision support, clinician education, access to active care, imaging-report reform, patient materials and audit feedback. A cluster RCT found a multifaceted implementation strategy can be compared directly with passive dissemination, but implementation effects depend on system design (Riis 2016, PMID 27769263).

Risk-stratified care improved outcomes in the original UK STarT Back trial but not in every replication (Hill 2011, PMID 21963002; Cherkin 2018, PMID 29790073). Guidelines must specify delivery, not only recommendations.

Evidence deepening: discriminating findings (2026-08-30)

The added evidence below was selected to change interpretation, not merely increase citation count. Each result is kept within its studied phenotype and design.

Evidence Quantified or mechanistic finding Consequence for interpretation
Recent clinical practice guidelines for the management of low back pain: a global comparison (Zhou 2024, PMID 38693474) A global comparison identified 22 recent guidelines of middle or high AGREE-II quality. Recommendation discordance persists even after methodological screening.
What does best practice care for musculoskeletal pain look like? Eleven consistent recommendations from high-quality clinical practice guidelines: systematic review (Lin 2020, PMID 30826805) Across 44 musculoskeletal guidelines, 11 met high-quality criteria and yielded 11 recurring care principles including selective imaging, education and exercise. Cross-condition consensus is strongest for process and conservative first-line care.
Systematic Review to Inform a World Health Organization (WHO) Clinical Practice Guideline: Benefits and Harms of Structured Exercise Programs for Chronic Primary Low Back Pain in Adults (Verville 2023, PMID 37991647) The WHO exercise review found structured exercise versus no intervention reduced pain (SMD −0.33, 95% CI −0.58 to −0.08) and functional limitation (SMD −0.31, 95% CI −0.57 to −0.05). Moderate average effects support offering exercise, not mandating one modality.
Systematic Review to Inform a World Health Organization (WHO) Clinical Practice Guideline: Benefits and Harms of Transcutaneous Electrical Nerve Stimulation (TENS) for Chronic Primary Low Back Pain in Adults (Verville 2023, PMID 37991646) The WHO TENS review found an immediate pain mean difference of −0.90 (95% CI −1.54 to −0.26) across nine sham-controlled trials. Statistical benefit was marginal and short-term, explaining cautious recommendations.
Imaging for low back pain: is clinical use consistent with guidelines? A systematic review and meta-analysis (Jenkins 2018, PMID 29730460) A meta-analysis estimated 34.8% (95% CI 27.1–43.3) of lumbar imaging referrals inappropriate when judged by absence of red flags. Implementation failure remains substantial despite guideline agreement.
Evidence-based treatment recommendations for neck and low back pain across Europe: A systematic review of guidelines (Corp 2021, PMID 33064878) A European review found 17 guidelines from eight countries, seven rated high quality. Regional disagreement should be traced to scope, evidence date and value judgments.
ASPN interventional guideline (Sayed 2022, PMID 36510616) A pain-society guideline appraised established and emerging procedures across distinct low-back-pain sources. Procedure-specific eligibility should not be generalized into endorsement for imaging-defined DDD.
AANS/CNS fusion update: injection selection (Watters 2014, PMID 24980590) Medial-branch blocks were not supported as predictors of lumbar-fusion outcome. A test for facet-mediated pain cannot validate a disc-fusion indication.
AANS/CNS fusion update: economic outcomes (Ghogawala 2014, PMID 24980580) The historical chapter required preference-based quality-of-life measurement to calculate QALYs. Cost claims need time horizon, comparator and utility method, not charges alone.

Controversy carried forward

These additions narrow several claims but do not create a diagnostic gold standard. Where an imaging, molecular or treatment-response signal conflicts with sham-controlled, longitudinal or population evidence, the conflict is retained as a selection and transportability problem rather than resolved by vote.

Open questions

  • How should new basivertebral-ablation evidence be integrated into general low-back-pain guidelines? The 2026 Chinese consensus does not address it at all (Fischgrund 2018, PMID 29423885; Gao 2026, PMID 42660880)
  • Does a Level I/Grade B intradiscal-PRP recommendation survive a meta-analysis that finds no significant pooled benefit at very low certainty? (Gao 2026, PMID 42660880; Madrazo-Ibarra 2026, PMID 42852874)
  • Which DDD-specific interventions merit recommendations versus research-only statements? (Schneider 2022, PMID 34352363)
  • Can guideline language reduce harmful imaging labels? (Brinjikji 2015, PMID 25430861)
  • What implementation strategy improves active-care access while reducing low-value imaging and opioids? (Riis 2016, PMID 27769263)
  • How should patient preference be weighted when benefits are small and harms differ? (Cashin 2023, PMID 37014979)
  • Which guideline-recommended LBP interventions remain cost-effective outside high-income health systems? (Mathieson 2026, PMID 42945153)

References

  1. Qaseem A, Wilt TJ, McLean RM, et al. Noninvasive Treatments for Acute, Subacute, and Chronic Low Back Pain: A Clinical Practice Guideline From the American College of Physicians. Annals of internal medicine. 2017;166(7):514-530. PMID 28192789
  2. Cancelliere C, Hincapié CA. Management of Adults with Chronic Primary Low Back Pain: Introduction to the Special Series of Systematic Reviews to Inform a World Health Organization (WHO) Clinical Guideline. Journal of occupational rehabilitation. 2023;33(4):615-617. PMID 37991650
  3. Chou R, Baisden J, Carragee EJ, et al. Surgery for low back pain: a review of the evidence for an American Pain Society Clinical Practice Guideline. Spine. 2009;34(10):1094-109. PMID 19363455
  4. Navani A, Manchikanti L, Albers SL, et al. Responsible, Safe, and Effective Use of Biologics in the Management of Low Back Pain: American Society of Interventional Pain Physicians (ASIPP) Guidelines. Pain physician. 2019;22(1S):S1-S74. PMID 30717500
  5. Chou R, Deyo R, Friedly J, et al. Systemic Pharmacologic Therapies for Low Back Pain: A Systematic Review for an American College of Physicians Clinical Practice Guideline. Annals of internal medicine. 2017;166(7):480-492. PMID 28192790
  6. Brinjikji W, Luetmer PH, Comstock B, et al. Systematic literature review of imaging features of spinal degeneration in asymptomatic populations. AJNR. American journal of neuroradiology. 2015;36(4):811-6. PMID 25430861
  7. Riis A, Jensen CE, Bro F, et al. A multifaceted implementation strategy versus passive implementation of low back pain guidelines in general practice: a cluster randomised controlled trial. Implementation science : IS. 2016;11(1):143. PMID 27769263
  8. Hayden JA, Ellis J, Ogilvie R, et al. Exercise therapy for chronic low back pain. The Cochrane database of systematic reviews. 2021;9(9):CD009790. PMID 34580864
  9. Fleckenstein J, Floessel P, Engel T, et al. Individualized Exercise in Chronic Non-Specific Low Back Pain: A Systematic Review with Meta-Analysis on the Effects of Exercise Alone or in Combination with Psychological Interventions on Pain and Disability. The journal of pain. 2022;23(11):1856-1873. PMID 35914641
  10. Cashin AG, Wand BM, O'Connell NE, et al. Pharmacological treatments for low back pain in adults: an overview of Cochrane Reviews. The Cochrane database of systematic reviews. 2023;4(4):CD013815. PMID 37014979
  11. Price MR, Cupler ZA, Hawk C, et al. Systematic review of guideline-recommended medications prescribed for treatment of low back pain. Chiropractic & manual therapies. 2022;30(1):26. PMID 35562756
  12. Shamliyan TA, Staal JB, Goldmann D, et al. Epidural steroid injections for radicular lumbosacral pain: a systematic review. Physical medicine and rehabilitation clinics of North America. 2014;25(2):471-89.e1-50. PMID 24787344
  13. Fischgrund JS, Rhyne A, Franke J, et al. Intraosseous basivertebral nerve ablation for the treatment of chronic low back pain: a prospective randomized double-blind sham-controlled multi-center study. European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society. 2018;27(5):1146-1156. PMID 29423885
  14. Khalil JG, Smuck M, Koreckij T, et al. A prospective, randomized, multicenter study of intraosseous basivertebral nerve ablation for the treatment of chronic low back pain. The spine journal : official journal of the North American Spine Society. 2019;19(10):1620-1632. PMID 31229663
  15. Phillips FM, Slosar PJ, Youssef JA, et al. Lumbar spine fusion for chronic low back pain due to degenerative disc disease: a systematic review. Spine. 2013;38(7):E409-22. PMID 23334400
  16. Willems P. Decision making in surgical treatment of chronic low back pain: the performance of prognostic tests to select patients for lumbar spinal fusion. Acta orthopaedica. Supplementum. 2013;84(349):1-35. PMID 23427903
  17. Rao MJ, Cao SS. Artificial total disc replacement versus fusion for lumbar degenerative disc disease: a meta-analysis of randomized controlled trials. Archives of orthopaedic and trauma surgery. 2014;134(2):149-58. PMID 24323061
  18. Wei J, Song Y, Sun L, et al. Comparison of artificial total disc replacement versus fusion for lumbar degenerative disc disease: a meta-analysis of randomized controlled trials. International orthopaedics. 2013;37(7):1315-25. PMID 23645003
  19. Manchikanti L, Navani R, Navani A, et al. Comprehensive Evidence-Based Guidelines for Regenerative Therapies in the Management of Chronic Low Back Pain: 2025 Update from the American Society Of Interventional Pain Physicians (ASIPP). Pain physician. 2025;28(S7):S1-S119. PMID 41481869
  20. Gornet MF, Beall DP, Davis TT, et al. Allogeneic Disc Progenitor Cells Safely Increase Disc Volume and Improve Pain, Disability, and Quality of Life in Patients With Lumbar Disc Degeneration-Results of an FDA-Approved Biologic Therapy Randomized Clinical Trial. International journal of spine surgery. 2024;18(3):237-248. PMID 38925869
  21. Pers YM, Soler-Rich R, Vadalà G, et al. Allogenic bone marrow-derived mesenchymal stromal cell-based therapy for patients with chronic low back pain: a prospective, multicentre, randomised placebo controlled trial (RESPINE study). Annals of the rheumatic diseases. 2024;83(11):1572-1583. PMID 39393844
  22. Downie A, Williams CM, Henschke N, et al. Red flags to screen for malignancy and fracture in patients with low back pain: systematic review. BMJ (Clinical research ed.). 2013;347:f7095. PMID 24335669
  23. Verhagen AP, Downie A, Popal N, et al. Red flags presented in current low back pain guidelines: a review. European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society. 2016;25(9):2788-802. PMID 27376890
  24. Hill JC, Whitehurst DG, Lewis M, et al. Comparison of stratified primary care management for low back pain with current best practice (STarT Back): a randomised controlled trial. Lancet (London, England). 2011;378(9802):1560-71. PMID 21963002
  25. Cherkin D, Balderson B, Wellman R, et al. Effect of Low Back Pain Risk-Stratification Strategy on Patient Outcomes and Care Processes: the MATCH Randomized Trial in Primary Care. Journal of general internal medicine. 2018;33(8):1324-1336. PMID 29790073
  26. Schneider BJ, Hunt C, Conger A, et al. The effectiveness of intradiscal biologic treatments for discogenic low back pain: a systematic review. The spine journal : official journal of the North American Spine Society. 2022;22(2):226-237. PMID 34352363
  27. Zhou T, Salman D, McGregor AH. Recent clinical practice guidelines for the management of low back pain: a global comparison. BMC musculoskeletal disorders. 2024;25(1):344. PMID 38693474
  28. Lin I, Wiles L, Waller R, Goucke R, Nagree Y, Gibberd M, et al. What does best practice care for musculoskeletal pain look like? Eleven consistent recommendations from high-quality clinical practice guidelines: systematic review. British journal of sports medicine. 2020;54(2):79-86. PMID 30826805
  29. Verville L, Ogilvie R, Hincapié CA, Southerst D, Yu H, Bussières A, et al. Systematic Review to Inform a World Health Organization (WHO) Clinical Practice Guideline: Benefits and Harms of Structured Exercise Programs for Chronic Primary Low Back Pain in Adults. Journal of occupational rehabilitation. 2023;33(4):636-650. PMID 37991647
  30. Verville L, Hincapié CA, Southerst D, Yu H, Bussières A, Gross DP, et al. Systematic Review to Inform a World Health Organization (WHO) Clinical Practice Guideline: Benefits and Harms of Transcutaneous Electrical Nerve Stimulation (TENS) for Chronic Primary Low Back Pain in Adults. Journal of occupational rehabilitation. 2023;33(4):651-660. PMID 37991646
  31. Jenkins HJ, Downie AS, Maher CG, Moloney NA, Magnussen JS, Hancock MJ, et al. Imaging for low back pain: is clinical use consistent with guidelines? A systematic review and meta-analysis. The spine journal : official journal of the North American Spine Society. 2018;18(12):2266-2277. PMID 29730460
  32. Corp N, Mansell G, Stynes S, Wynne-Jones G, Morsø L, Hill JC, et al. Evidence-based treatment recommendations for neck and low back pain across Europe: A systematic review of guidelines. European journal of pain (London, England). 2021;25(2):275-295. PMID 33064878
  33. Sayed D, Grider J, Strand N, Hagedorn JM, Falowski S, Lam CM, et al. The American Society of Pain and Neuroscience (ASPN) Evidence-Based Clinical Guideline of Interventional Treatments for Low Back Pain. Journal of pain research. 2022;15:3729-3832. PMID 36510616
  34. Watters WC, Resnick DK, Eck JC, Ghogawala Z, Mummaneni PV, Dailey AT, et al. Guideline update for the performance of fusion procedures for degenerative disease of the lumbar spine. Part 13: injection therapies, low-back pain, and lumbar fusion. Journal of neurosurgery. Spine. 2014;21(1):79-90. PMID 24980590
  35. Ghogawala Z, Whitmore RG, Watters WC, Sharan A, Mummaneni PV, Dailey AT, et al. Guideline update for the performance of fusion procedures for degenerative disease of the lumbar spine. Part 3: assessment of economic outcome. Journal of neurosurgery. Spine. 2014;21(1):14-22. PMID 24980580
  36. Skelly AC, Kansagara D, Oswald J, et al. Assessment and Treatment of Acute Low Back Pain: A Multidisciplinary Clinical Practice Guideline. Pain medicine (Malden, Mass.). 2026. doi: 10.1093/pm/pnag110. PMID 42687437
  37. Manchikanti L, Navani A, Jordan S, et al. Regenerative Therapies in the Management of Chronic Low Back Pain from Evidence to Practice: An Analytical Summary of the 2025 Comprehensive Evidence-Based Guidelines. Pain physician. 2026;29(6):E531-E552. PMID 42804305
  38. Gao B, Chai R, Wang G, et al. Multidisciplinary expert consensus on clinical diagnosis and therapies for low back pain. Bone research. 2026;14(1):92. doi: 10.1038/s41413-026-00572-y. PMID 42660880
  39. Madrazo-Ibarra A, de la Huerta-Meza D, Gutierrez-Naranjo JM, et al. Preparation methods and clinical outcomes of platelet-rich plasma for chronic discogenic low back pain: A systematic review and meta-analysis of randomized controlled trials. PM & R. 2026. doi: 10.1002/pmrj.70216. PMID 42852874
  40. Mathieson S, Underwood M, Ibrahim M, Hua Z, Zhu Z, Ferreira PH, et al. Cost-effectiveness of recommended interventions for managing low back pain: A systematic review. PLoS medicine. 2026;23(10):e1005273. PMID 42945153